Walter Noordzij
dr.
In my profession as a nuclear medicine physician, I’m involved in both clinical and scientific applications of nuclear medicine and radiology modalities. My main interests include haematology, general oncology, radio-immunotherapy, and especially the implementation of new therapeutic strategies. Currently, I have a special interest in imaging post-transplant lymphoproliferative disease, as well as radio-immunotherapy in chemotherapy refractory (non)-Hodgkin’s lymphoma.
Parotid gland fat related Magnetic Resonance image biomarkers improve prediction of late radiation-induced xerostomia
Published in: Radiotherapy and Oncology
Access to document
10.1016/j.radonc.2018.06.012
document
Purpose: This study investigated whether Magnetic Resonance image biomarkers (MR-IBMs) were associated with xerostomia 12 months after radiotherapy (Xer(12m)) and to test the hypothesis that the ratio of fat-to-functional parotid tissue is related to Xer(12m). Additionally, improvement of the reference Xer(12m) model based on parotid gland dose and baseline xerostomia, with MR-IBMs was explored. Methods: Parotid gland MR-IBMs of 68 head and neck cancer patients were extracted from pre-treatment T1-weighted MR images, which were normalized to fat tissue, quantifying 21 intensity and 43 texture image characteristics. The performance...
Lisanne V. van Dijk, Maria Thor, Roel J. H. M. Steenbakkers, Aditya Apte, Tian-Tian Zhai, Ronald Borra, Walter Noordzij, Cherry Estilo, Nancy Lee, Johannes A. Langendijk, Joseph O. Deasy, Nanna M. Sijtsema
Response to: Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma
Published in: Journal of Hepatology
Access to document
10.1016/j.jhep.2018.04.014
False-positive findings on 6-[18F]fluor-L-3,4-dihydroxyphenylalanine PET (F-18-FDOPA-PET) performed for imaging of neuroendocrine tumors
Published in: European Journal of Endocrinology
Access to document
10.1530/EJE-18-0321
Background/aim: PET with 6-[18F]fluor-L-3,4-dihydroxyphenylalanine (F-18-FDOPA) has been shown to be a useful imaging tool with a high sensitivity for the visualization of neuroendocrine tumors (NETs). F-18-FDOPA uptake in tumors other than NETs has been suggested previously, but data on this phenomenon are limited. We therefore studied the non-physiological, false-positive uptake of F-18-FDOPA in a large population of patients with a NET or with a high clinical suspicion of harboring a NET. Patients and methods: Retrospective single-center study among adult patients in whom F-18-FDOPA PET scintigraphy was performed between...
Annika M A Berends, Michiel N Kerstens, Janne W Bolt, Thera P Links, Esther Korpershoek, Ronald R de Krijger, Annemiek M E Walenkamp, Walter Noordzij, Boudewijn van Etten, Gursah Kats-Ugurlu, Ah Brouwers, A N A van der Horst-Schrivers
Lactate dehydrogenase levels and F-18-FDG PET/CT metrics differentiate between mediastinal Hodgkin’s lymphoma and primary mediastinal B-cell lymphoma
Published in: Nuclear Medicine Communications
Access to document
10.1097/MNM.0000000000000840
document
PURPOSE: This study aims to investigate whether clinical, laboratory, and fluorine-18-fluorodeoxyglucose (F-FDG) PET/CT findings can discriminate between mediastinal Hodgkin’s lymphoma and primary mediastinal B-cell lymphoma (PMBCL). PATIENTS AND METHODS: This retrospective study included 56 patients (42 with mediastinal Hodgkin’s lymphoma and 14 with PBMCL). Differences in clinical, laboratory, and F-FDG PET/CT metrics were assessed between Hodgkin’s lymphoma and PMBCL. RESULTS: Lactate dehydrogenase (LDH) and F-FDG PET/CT-based maximum tumor diameter, lesion-to-liver ratio maximum standardized uptake value (SUVmax), and lesion-to-liver ratio peak standardized uptake value (SUVpeak) were all significantly higher...
Rayan H M Alkhawtani, Walter Noordzij, Andor W J M Glaudemans, Rozemarijn S van Rijn, Hilde T van der Galiën, Hans Balink, Marcel Nijland, Hugo J A Adams, Gerwin Huls, Tom van Meerten, Thomas C Kwee
Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging F-18-FDG PET Imaging Biomarkers in Patients with Esophageal Cancer
Published in: Radiology
Access to document
10.1148/radiol.2018172229
document
Purpose: To assess the value of baseline and restaging fluorine 18 (F-18) fluorodeoxyglucose (FDG) positron emission tomography (PET) radiomics in predicting pathologic complete response to neoadjuvant chemotherapy and radiation therapy (NCRT) in patients with locally advanced esophageal cancer. Materials and Methods: In this retrospective study, 73 patients with histologic analysisconfirmed T1/N1-3/M0 or T2-4a/N0-3/M0 esophageal cancer were treated with NCRT followed by surgery (Chemoradiotherapy for Esophageal Cancer followed by Surgery Study regimen) between October 2014 and August 2017. Clinical variables and radiomic features from baseline and restaging F-18-FDG PET...
Roelof J Beukinga, Jan Binne Hulshoff, Véronique E M Mul, Walter Noordzij, Gursah Kats-Ugurlu, Riemer H J A Slart, John T M Plukker